Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis (original) (raw)
Related papers
Cardiovascular comorbidities in psoriasis (Review)
Experimental and Therapeutic Medicine, 2021
Long considered a skin-limited condition, psoriasis is currently defined as a chronic, immune-mediated inflammatory disease, presenting, besides the skin changes, important systemic manifestations, the most common being: psoriatic arthritis, cardiovascular disease, metabolic syndrome, diabetes, inflammatory bowel disease and nonalcoholic steatohepatitis. It is a disease with a strong psycho-emotional and social impact, both through skin changes such as pruritic, scaly erythematous plaques, and through the association of comorbidities that influence morbidity and mortality. It has been shown that psoriasis is an independent cardiovascular risk factor, with patients developing ischemic heart disease/acute coronary syndrome, hypertension, peripheral arterial disease, or stroke. The chronic inflammatory status of psoriasis and the production of specific cytokines may be the etiopathogenic link to atherosclerosis and cardiovascular disease. Biological therapy may affect atherosclerosis, leading to the arrest of the evolution or even regressing the changes in the atheromatous plaque. The aim of this review was to re-evaluate the current knowledge regarding the cardiovascular comorbidities associated with psoriasis for optimal management of the patients.
Journal of Pakistan Association of Dermatology, 2019
Objectives Psoriasis is a chronic, inflammatory skin disease. Nowadays, its association with metabolic and vascular disorders is increasingly recognized. The study was conducted to know the association of psoriasis with metabolic syndrome (MS). Methods A hospital-based case-control study was conducted. Fifty psoriatic patients and 48 controls were recruited. Data collected included disease duration, history of smoking/alcoholism, type and severity of psoriasis, body mass index (BMI), waist circumference, blood pressure and body surface area (BSA) involvement,. Fasting blood glucose and lipid profile were measured in all patients. MS was diagnosed in presence of ≥3 criteria of the ATP III criteria. Results Patients had mild to severe psoriasis (PASI score 8.3-47). BSA affected ranged from 10% to 90%. The prevalence of MS was higher in psoriatic patients as compared to controls, but without statistical significance (12% vs. 6%, OR: 2.21, p: 0.48). MS components analyzed separately, s...
Cardiovascular and Metabolic Comorbidities of Psoriasis
Dermatology Case Reports
Pathogenetic mechanisms of CVD in psoriasis patients appear to be of a complex nature and remain unclear. The development of atherosclerosis and its increased prevalence may be partially explained by the presence of atherosclerotic risk factors, e.g., diabetes, hypertension, obesity, and hyperlipidemia as well as by the chronic inflammatory processes that are commonly observed in psoriasis (Figure 1) [11] Both of these pathological conditions involve genetic, immunological, and environmental factors, which may modify the clinical expression of psoriasis and atherosclerosis substantially [10,12]
Psoriasis: an opportunity to identify cardiovascular risk
British Journal of Dermatology, 2009
Psoriasis is highly prevalent and is associated with skin-associated complaints as well as arthritis, depression and a lower quality of life. Recently, it has been demonstrated that not only do patients with psoriasis have an increased prevalence of cardiovascular risk factors, but an increased risk of myocardial infarction, and for those with severe disease, increased mortality. Dermatologists and other health professionals need to be cognizant of this association and ensure that cardiovascular risk factors are evaluated and treated appropriately in those patients with psoriasis. We review the association between psoriasis, atherosclerosis and inflammation, as well as some treatable cardiovascular risk factors that may prove beneficial in reducing a patient's cardiovascular risk.
Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients
Atherosclerosis, 2007
Psoriasis is a chronic inflammatory skin disease that is associated with an increased cardiovascular risk profile. The systemic inflammation present in psoriasis, various systemic treatments for psoriasis and an increased prevalence of unhealthy life style factors may all contribute to this unfavorable risk profile. The purpose of this article is to provide an overview of what is known about these risk factors in psoriasis, the way they influence the cardiovascular risk of psoriasis patients, and what can be done to reduce this risk.
Psoriasis and Cardiovascular Risk Profile: A Comprehensive Review
Journal of Pharmaceutical Research International, 2021
Psoriasis is an inflammatory immune-mediated, chronic skin disease with many co-morbidities involving complex pathogenic interactions between the innate and adaptive immune systems. In people living with psoriasis, there is an increased probability of having other health conditions such as cardiovascular illnesses. A growing number of studies show that classic risk factors which lead to cardiovascular diseases and metabolic syndromes are common in psoriasis patients, leading to a more significant cardiovascular burden. The present article aims to synthesize what is known in the literature concerning the epidemiological and clinical data relating to cardiovascular risk factors and psoriasis. The many pathophysiological mechanisms which justify this association for stratification of the risk profile in psoriatic patients are also reviewed, along with the implementation of different cardiovascular prevention strategies. The benefits and drawbacks of the numerous therapies frequently us...
Psoriasis and Cardiovascular Comorbidities
2018
DOI: 10.21276/sjams.2017.5.12.74 Abstract: Psoriasis is one of the most prevalent T-cell-mediated chronic inflammatory disorders affecting the skin, scalp, nails, and joints. Its pathophysiology is characterized by immune responses mediated by type 1 and type17 helper T lymphocytes and synthesis of various cytokinesthat produce inflammation of the skin and joints. In recent years, several studies demonstrated that psoriasis is associated with an increased risk of various cardiovascular diseases.This report synthesizes the current understanding of the prevalence and characteristics of cardiovascular comorbidities in patients with psoriatic disease, and the importance of screening for and treating modifiable cardiometabolic risk factors.
Journal of the European Academy of Dermatology and Venereology, 2010
Introduction Many epidemiological studies have associated psoriasis with an increased risk of coronary artery disease, resulting from a higher prevalence of cardiovascular risk factors in psoriasis patients compared with unmatched controls. However, the results of epidemiological studies vary depending upon the populations studied. The aim of this systemic review was to evaluate the risk of diabetes, hypertension, dyslipidaemia and obesity in adults with plaque psoriasis. In addition, we assessed the relationship between the risk of cardiovascular risk factors and psoriasis severity.
Cardiovascular aspects of psoriasis: an updated review
International Journal of Dermatology, 2013
Psoriasis, a systemic inflammatory disease, is associated with enhanced atherosclerosis and risk of cardiovascular (CV) disease, which may account for higher morbidity and mortality rates in psoriatic patients. It especially applies to younger psoriatic patients with more severe disease, reducing their life expectancy. The aim of the study was to review the literature on CV disease in psoriasis as well as the pathogenic mechanisms shared between psoriasis and atherosclerosis. Moreover, casecontrol and cohort studies published between 2006 and 2011 were selected for metaanalysis. The meta-analysis indicates elevated risk of cardiovascular events in psoriatic patients in relation to non-psoriatic controls (OR 1.28; 95% CI 1.18-1.38). It is suggested that the treatment of the inflammatory processes involved in the pathogenesis of both psoriasis and atherosclerosis may be beneficial in reducing the CV risk in psoriatic patients. Further in-depth investigations, including prospective studies, are needed to enable more effective management of psoriatic patients in the future.